Takeda gets UK nod for rare blood disorder treatment Ruchika Sharma14 May 2025 1:30 PM ISTTakeda UK Ltd. has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for rADAMTS13 (ADZYNMA), a treatment to treat...
Eris Lifesciences designates Gopal Agrawal, Nita Borkar in leadership roles Ruchika Sharma2 April 2025 1:16 PM ISTMumbai: Eris Lifesciences Limited, an Indian branded formulations manufacturing company, has designated Gopal Agrawal and Nita Borkar in...
Takeda gets EMA nod for additional subcutaneous administration of Takhzyro in Hereditary Angioedema patients Ruchika Sharma25 Feb 2025 10:30 AM ISTZurich: Takeda has announced that the European Medicines Agency (EMA) has given approval for an additional 2 mL pre-filled pen option for...
Julie Kim to succeed Christophe Weber as CEO of Takeda Ruchika Sharma30 Jan 2025 5:06 PM ISTOsaka: Takeda has announced that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda's...
Takeda gets Japenese nod for Hyqvia 10% SC injection set for Agammaglobulinemia Ruchika Sharma27 Dec 2024 12:32 PM ISTOsaka: Takeda has announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA [Immune Globulin...
Submit Separate Retrospective, Prospective Study data of subjects: CDSCO Panel Tells Takeda on Velaglucerase alfa study Dr. Divya Colin15 July 2024 6:00 PM ISTNew Delhi: Regarding the post-marketing surveillance study of the drug major Takeda Pharmaceutical's Velaglucerase alfa injection, the Subject Expert...
Takeda gets European Commission approval for Fruzaqla for previously treated metastatic Colorectal cancer Ruchika Sharma23 Jun 2024 12:00 PM ISTFRUZAQLA is a selective oral inhibitor of all three VEGF receptors (-1, -2 and -3). VEGFR inhibitors play a pivotal role in blocking tumor...
Takeda announces Phase 3 topline results for Soticlestat in patients with Dravet Syndrome, Lennox-Gastaut Syndrome Ruchika Sharma18 Jun 2024 4:14 PM ISTOsaka: Takeda has announced topline data from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind...
Takeda signs option agreement with Ascentage Pharma to enter into exclusive global license for Olverembatinib Ruchika Sharma16 Jun 2024 10:30 AM ISTJapan: Takeda has announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for...
Takeda Biopharma names Annapurna Das as General Manager for India Operations Ruchika Sharma17 May 2024 11:36 AM ISTMumbai: Takeda Biopharmaceuticals India Pvt Ltd (formerly known as Baxalta Bioscience India Private Limited), part of a global values-based,...
India becoming attractive for clinical trials: Pharma industry leaders Ruchika Sharma29 April 2024 2:33 PM ISTNew Delhi: Experts from the pharmaceutical sector have noted that over the last decade, clinical trials in India have undergone significant...
Takeda gets USFDA nod for Entyvio subcutaneous administration for Crohn's disease Ruchika Sharma21 April 2024 10:00 AM ISTOsaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO (vedolizumab) subcutaneous (SC)...
